Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, approved for treating T2D and obesity, hold potential for MASH patients, offering cardiovascular benefits and MASH improvement [186]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.